Edaravone oral - Auzone Biological Technology
Alternative Names: TTYP 01Latest Information Update: 22 Jan 2025
Price :
$50 *
At a glance
- Originator Suzhou Auzone Biological Technology
- Class Anti-ischaemics; Antidementias; Antihaemorrhagics; Antiparkinsonians; Hepatoprotectants; Neuroprotectants; Pyrazolones; Small molecules; Vascular disorder therapies
- Mechanism of Action Antioxidants; Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Stroke
- Phase II Pervasive child development disorders
- No development reported Amyotrophic lateral sclerosis
Most Recent Events
- 07 Jan 2025 Phase-II clinical trials in Pervasive child development disorders (In adolescents, In children) in China (PO) (NCT06757504)
- 27 Dec 2024 Shanghai Auzone Biological plans a phase II trial for Autistic disorder (In children, In adolescents) in China (PO), in December 2024 (NCT06757504)
- 17 Jun 2024 Auzone Biological Technology completes a phase-III clinical trials in Stroke in China (PO) (NCT06648304)